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Advanced glycation end products (AGEs) have been linked to
the pathogenesis of diabetic nephropathy. Here we tested
the effect of AGE-modified bovine serum albumin (AGE-BSA)
on differentiated mouse podocytes in culture. Differential
display and real-time PCR analyses showed that in addition to
neuropilin-1, the entire signaling receptor complex of
neuropilin-2, semaphorin-3A, and plexin-A1, was significantly
reduced by AGE-BSA as was neuropilin-1 protein. The effect
was specific for podocytes compared to isolated mesangial
and tubular epithelial cells. Further, AGE-BSA was not toxic to
podocytes. Neutopilin-1 expression was decreased in
glomeruli of diabetic db/db mice compared to their non-
diabetic littermates. Transcripts of both neuropilins were
found to be decreased in renal biopsies from patients with
diabetic nephropathy compared to transplant donors.
Podocyte migration was inhibited by AGE-BSA with similar
results found in the absence of AGE-BSA when neuropilin-1
expression was down-regulated by siRNA. In contrast,
podocyte migration was stimulated by overexpression of
neuropilin-1 even in the presence of AGE-BSA. Our study
shows that AGE-BSA inhibited podocyte migration by down-
regulating neuropilin-1. The decreased migration could lead
to adherence of uncovered areas of the glomerular basement
membrane to Bowman’s capsule contributing to focal
glomerulosclerosis.
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It has been demonstrated that advanced glycation end
products (AGE) formation is increased in diabetes due to
chronic hyperglycemia.1–3 Specific receptors (RAGE) are able
to recognize AGEs and initiate various signal transduction
pathways resulting in enhanced oxidative stress and tran-
scriptional activation.3,4 These receptors are localized on
podocytes.4
Mesangial expansion, a thickening of the glomerular
basement membrane, and loss of negatively charged proteo-
glycans in the glomerular basement membrane, were
considered as important structural changes leading to
diabetic nephropathy.5,6 However, recent data suggest that
the loss of proteoglycans occurs, if at all, late in the course of
diabetic nephropathy.7 However, significant reduction of the
podocyte number per glomerulus and/or podocyte damage
occurs early in experimental models of diabetic nephropathy
as well as in human diabetic nephropathy.8–11 Although it has
been previously shown that podocytes express RAGE, little is
known of potential genetic programs induced by AGEs in
these cells. To obtain a better insight into this subject, gene
expression was monitored in cultured differentiated mouse
podocytes exposed to AGE-modified bovine serum albumin
(AGE-BSA) using differential display.
RESULTS
Analysis of AGE-BSA mediated gene expression differences in
mouse podocytes
We investigated gene expression in a well-defined differ-
entiated conditionally immortalized mouse podocytes,12
which were exposed to either 5 mg/ml AGE-BSA or
control-BSA (Co-BSA) using differential display analysis.
After glycation, AGE-BSA was characterized by a 58-fold
higher Ne-carboxy-methyl-lysine (CML) concentration com-
pared to the Co-BSA (11.6 nmol/mg protein versus 0.2 nmol/
mg protein in Co-BSA) and 6-fold higher pentosidine
(4.9 pmol/mg protein versus 0.8 pmol/mg protein in Co-
BSA) concentrations. Compared with concentrations mea-
sured in the serum of patients with type 2 diabetes,13,14 the
used CML concentration was 22.5 times higher but the
pentosidine concentration was 5.7 times lower in our cell
culture experiments. Co-BSA and AGE-BSA preparations did
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not contain residual glucose after dialysis (glucose concen-
tration o0.3 mmol/l). Fluorescence readings were similar to
previously reported findings.15 (5 days: 710±1.4, 15 days:
972±27, 20 days: 1109±19, 50 days:1173±30 ex 335 nm/
em. 420 nm, n¼ 6).
Figure 1 shows that podocytes were differentiated and
expressed synaptopodin. AGE-BSA did not influence synap-
topodin staining. Gene expression was analyzed in podocytes
exposed for 24 h to 5 mg/ml AGE-BSA compared with 5 mg/ml
Co-BSA. Partial results from the differential display gel are
shown in Figure 2a. We found 188 fragments differentially
amplified. From this number 111 PCR bands were upregu-
lated by AGE-BSA compared to the corresponding Co-BSA
and 77 fragments were downregulated (data not shown). We
have so far identified the sequence for 22 fragments (Table 1).
AGE-BSA inhibits the expression of neuropilin-1 and neuro-
pilin-2 mRNA and protein expression in mouse podocytes
Differential display assays revealed neuropilin 1 (NRP1) as
one of the genes, which was downregulated in podocytes by
AGE-BSA (Figure 2a). Real-time PCR demonstrated that
AGE-BSA reduced mRNA expression of NRP1 by 60±19%
compared to Co-BSA treatment (Figure 2b). As NRPs exist in
two isoforms, NRP1 and NRP2, that are found in mouse
podocytes,16,17 we also tested whether AGE-BSA modified the
expression of NRP2. mRNA expression of NRP2 in podocytes
was also reduced by AGE-BSA compared with Co-BSA
(Figures 2b). NRP1 and NRP2 protein expressions were
significantly reduced in lysates from the AGE-BSA-treated
podocytes compared to the Co-BSA (Figure 2c; NRP1,
Co-BSA: 1.00±0.03, AGE-BSA:0.65±0.12*; NRP2, Co-BSA:
1.00±0.04, AGE-BSA:0.60±0.09* relative expression nor-
malized to vinculin, n¼ 10 for NRP1, n¼ 5 for NRP2,
*Po0.01 versus Co-BSA). NRP1 expression in two syngeneic
cell lines, mouse mesangial cells18 and mouse tubular cells,19
was present, but its expression was not reduced after AGE-
BSA incubation (Figure 2d).
AGE-BSA reduces the expression of genes involved in the
neuropilin-1 complex
NRP1 is a binding receptor for semaphorin-3A (Sema 3A)
and a coreceptor for the vascular endothelial growth factor
(VEGF)165.
20 Therefore, we investigated the effect of AGE-
BSA on genes involved in the NRP complex. We found that
the mRNA expressions of Sema 3A, Sema 3C, and Sema 3F,
but not of Sema 3B, is reduced by AGE-BSA (Figure 3a).
Moreover, PxA1 mRNA expression was significantly reduced
by AGE-BSA, but had no effect on the expression of PxA2,
PxA3, and PxB2 (Figure 3b).
AGE-BSA reduced podocyte migration ability through
suppression of NRP1
Recently, it was reported that AGE-BSA can inhibit
tubulogenesis and migration of kidney epithelial cells.21,22
Accumulating evidence suggests that NRP1 is involved in the
regulation of migration processes in different cell types.23,24
Therefore, we were interested in assessing the ability of AGE-
BSA to affect podocyte migration. 10% fetal calf serum (FCS)
induced a significant migration of podocytes (Figure 4a). In
comparison with 10% FCS, migration was significantly lower
in the presence of Co-BSA (Figure 4a). However, this
migration was even further significantly reduced when
AGE-BSA was used as stimuli (Figure 4a).
As NRP1 is a receptor for class 3A semaphorins and may
act as a coreceptor for VEGF165,
20 we tested the ability of
mouse VEGF165 to affect podocytes migration.
25,26 We first
analyzed the expression of VEGF receptor 2 (VEGFR2) in
podocytes and found that its expression as detected by
western blot was very low (data not shown). Similarly, real-
time PCR analysis demonstrated low amounts of VEGFR2
mRNA in podocytes compared to NRP1 expression. AGE-
BSA increased and not decreased VEGFR2 expression (NRP1,
Co-BSA: 9.7±0.41, AGE-BSA:10.38±0.27* DCT; VEGFR2,
Co-BSA:19.32±0.16#, AGE-BSA:17.75±0.20#* DCT, *Po0.05
versus Co-BSA, #Po0.001 versus NRP1 expression, n¼ 6).
These results demonstrate that VEGFR2 mRNA expression in
podocytes is approximately 1000-fold lower than the mRNA
of NRP1 for Co-BSA-treated cells.
Although 1 ng/ml VEGF slightly enhanced migration,
this effect was not significant (Figure 4b). 10 ng/ml
VEGF alone had no further effect (data not shown).
However, the presence of VEGF partially prevented the
reduction of migration induced by AGE-BSA (Figure 4b). In
addition, Co-BSA compared with 0.1% FCS stimulated
migration, indicating a small stimulatory effect albumin
(Figure 4b).
Co-BSA AGE-BSA
Negative control
Figure 1 | Immunocytological staining of podocytes for
synaptopodin incubated with AGE-BSA 5 mg/ml compared to
Co-BSA 5 mg/ml (original magnification 40 ). Expression of
the podocyte differentiation marker synaptopodin did not change
after treatment with AGE-BSA. Cells are differentiated and they
show signs of arboration. A negative control is shown in which
the primary antibody was replaced by normal goat serum.
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We next suppressed NRP1 expression by transiently
transfecting two different NRP1 siRNA primers or a scramble
control siRNA into podocytes. The ability of the two different
NRP1 siRNAs to inhibit NRP1 expression was tested with
semiquantitative RT-PCR (not shown) as well as by Western
blotting (Figure 5a). Downregulation of NRP1 expression led
to a significant reduction of the podocyte migration capacity
not only in Co-BSA or AGE-BSA-treated podocytes, but also
in podocytes exposed to 10% FCS (Figure 5a). We then
performed a contrast experiment by transient overexpression
of NRP1. A full-length cDNA of the mouse NRP1 gene was
cloned into the pcDNA3 vector. Podocytes were transfected
with pcDNA3NRP1 and overexpression was confirmed by
Western blots (Figure 5b and c). Transfection with the
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Figure 2 | NRP1 expression. (a) Differential display analysis of podocytes treated with 0.1% FCS, 0.1% FCS±Co-BSA, or 0.1% FCS±AGE-BSA
amplified with three different primer sets demonstrates a number of differentially regulated gene fragments. A small part of the gel is
shown as an example demonstrating up- as well as downregulation of various genes. The fragment in the box was excised, subcloned, and
sequenced. BLAST analysis revealed that this is the sequence encoding for a NRP1 gene. (b) Real-time RT-PCR analysis of NRP1 and NRP2
mRNA expression. AGE-BSA (5 mg/ml for 24 h) significantly reduced mRNA expressions of NRP1 and NRP2 compared to Co-BSA (n¼ 6,
*Po0.05, **Po0.03). (c) In addition, AGE-BSA also significantly reduced NRP1 and NRP2 protein expressions as determined by Western
blots. Equal loading was controlled by anti-vinculin antibody. (d) In contrast to podocytes, AGE-BSA failed to downregulate NRP1 mRNA
expression in mouse mesangial cells (MMC) and mouse cortical tubular cells (MCT). Real-time RT-PCR, n¼ 6.
Table 1 | Accession numbers of the gene fragments identified by differential display assay
gi|20071927|gb|BC026977.1| Mus musculus N-ethylmaleimide sensitive fusion protein attachment protein gamma, mRNA
gi|111308877|gb|BC120809.1| Mus musculus granzyme N, mRNA
gi|193639|gb|M96930.1| Mus musculus granzyme F gene
gi|50326|emb|X56989.1| Mus musculus CCP4 gene for cytotoxic cell proteinase 4
gi|2275034|emb|AJ000507.1| Mus musculus mRNA for homeodomain protein Meis2d
gi|13810107|emb|AL589699.4| Mouse DNA sequence from clone RP23-92G13 on chromosome 13 Contains the 3’ end of the gene for a novel protein
similar to KIAA0386,gi|23304629|emb|AL669844.20| Mouse DNA sequence from clone RP23-395O6 on chromosome 11 Contains the 3’ end of a novel
gene
gi|38014372|gb|BC060375.1| Mus musculus WD repeats and SOF domain containing 1, mRNA
gi|41223813|emb|AL928642.5| Mouse DNA sequence from clone RP24-191C1 on chromosome 4 Contains the gene for a novel protein similar to aldolase
1 A isoform Aldo1Mus gi|37805304|gb| BC060129.1| Mus musculus DNA sequence for neuropilin 1, mRNA (cDNA clone MGC:63314)
gi|34808711|gb| BC011073.2| Mus musculus perforin 1 (pore forming protein) (Prf1), mRNA
gi|33859856|gb|AC091783.9| Genomic sequence for Mus musculus, clone RP23-16G10
gi|57544782|gb|AC154829.2| Mus musculus BAC clone RP24-550F10 from chromosome 14
gi|25777708|gb|BC015547.2| Homo sapiens acyl-CoA thioesterase 11 (ACOT11), transcript variant 1, mRNA
gi|1679663|gb|U66473.1| Mus musculus preprogranzyme G gene
gi|77415359|gb|BC106101.1| Mus musculus NSFL1 (p97) cofactor (p47), mRNA
gi|74205898|dbj|AK137088.1| Mus musculus RIKEN full-length enriched library, clone:9430070A02 product:syntaxin binding protein
3gi|24527684|emb|AL928719.6| Mouse DNA sequence from clone RP23-419G21 on chromosome 2
gi|38014372|gb|BC060375.1| Mus musculus WD repeats and SOF domain containing 1, mRNA
gi|54887393|gb|BC085135.1| Mus musculus nucleolar protein 5, mRNA
gi|100818169|gb|BC050875.1| Mus musculus Rho GTPase activating protein 11A, mRNA
gi|89357941|gb|NM030228.2| Mus musculus growth arrest specific 2 like 1 (Gas2l1) protein
The fragments were reamplified, subcloned, and the sequences were subjected to a BLAST search for gene identification.
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pcDNA3 empty vector did not affect the ability of AGE-BSA
to reduce the NRP1 protein expression (Figure 5b). Forced
overexpression of NRP1 increased podocyte migration ability
even in cells treated with AGE-BSA (Figure 5d).
No cytotoxicity of AGE-BSA for podocytes
To rule out that is the reduced podocytes migration is the
presence of AGE-BSA is simply caused by cytotoxicity, we
measured lactate dehydrogenase release from damaged cells.
Neither Co-BSA nor AGE-BSA was toxic for podocytes (data
not shown).
Total suppression of NRP1 with siRNA, but not AGE-BSA,
induced apoptosis of podocytes
Recently, it was demonstrated that NRP1 is involved in
podocyte survival.16 Therefore, we addressed the possibility
of NRP1 suppression by AGE-BSA to induced podocytes
apoptosis. We used CaspAce-FITC-VAD-FMK in situ marker
as one test for apoptosis.27 Untransfected podocytes (data no
shown) or podocytes transfected with co-siRNA showed no
CaspAce-FITC-VAD-FMK staining in the presence of Co-
BSA or AGE-BSA (Figure 6a). However, complete silencing of
NRP1 expression with a specific siRNA induced uptake of the
CaspAce-FITC-VAD-FMK even in the absence of AGE-BSA
(Figure 6b). Suppression of NRP1 mRNA expression by the
NRP1 siRNA transfection was controlled by semiquantitative
RT-PCR. As shown in Figure 6c, NRP1 siRNA, but not co-
siRNA, suppressed very specifically the NRP1, but not NRP2
or glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
mRNA expression.
In addition, we also assessed apoptosis by DNA laddering.
In accordance with previous studies,28 AGE-BSA failed to
induce fragmentation of genomic DNA isolated from
podocytes (Figure 6d). However, complete suppression of
NRP1 by siRNA induced DNA fragmentation (Figure 6d).
NRP1 suppression affects podocyte proliferation
We further analyzed the potential role of NRP1 in podocyte
proliferation. AGE-BSA significantly reduced bromodeoxy-
uridine (BrdU) incorporation compared to Co-BSA-treated
cells whereas 1 ng/ml VEGF for 24 h stimulated proliferation
(Figure 7a). Addition of VEGF to AGE-BSA did not attenuate
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Figure 3 | AGE-BSA reduced the mRNA expression of other
members involved in the NRP1 signaling complex. (a)
Expressions of neuropilin ligands semaphorin (Sema) 3A, 3B, 3C,
and 3F in podocytes. Except for Sema 3B, mRNA expressions of all
other semaphorins were significantly reduced by AGE-BSA
incubation (real-time RT-PCR; n¼ 6, *Po0.05, **Po0.01, versus
Co-BSA). (b) Expressions of neuropilins’ signaling-receptors Plexin
(Px) A1, A2, A3, and B2 in podocytes. The major coreceptors of
NRP1, PxA1, were significantly reduced by AGE-BSA (real-time
RT-PCR; n¼ 6, *Po0.01 versus Co-BSA).
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Figure 4 | AGE-BSA suppressed migration of podocytes. (a)
Podocyte migration ability was tested in a transwell migration
assay system. Addition of AGE-BSA significantly reduced podocyte
migration compared to the Co-BSA. 10% FCS was used as a
positive control for the migration assay and significantly induced
migration. (n¼ 16, *Po0.05 versus Co-BSA, #Po0.01 versus 10%
FCS). (b) Podocytes migration in transwell assay was also tested
using RPMI 1640 medium containing 0.1% FCS (control), 1 ng/ml
VEGF165, Co-BSA 5 mg/ml, AGE-BSA 5 mg/ml, or 1 ng/ml VEGF164
together with Co-BSA or AGE-BSA. VEGF was not able to
significantly enhanced migration of podocytes, but attenuated
the AGE-BSA-mediated reduction in migration (n¼ 16 *Po0.05
versus Co-BSA). Co-BSA alone significantly stimulated migration
compared to 0.1% FCS alone suggesting an effect of albumin
(n¼ 16 *Po0.05 versus Co-BSA). N.S.¼ not significant.
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the reduced proliferation and even further reduced
proliferation (Figure 7a). Transient transfection of podocytes
with NRP1 siRNA, but not with co-siRNA, significantly
reduced BrdU incorporation (Figure 7b).
Neuropilin-1 expression is also reduced in diabetic mice
We investigated whether a glomerular suppression of NRP1
occurs in an in vivo model of diabetic nephropathy. We used
db/db mice at 4 months, a widely used model of type 2
diabetes.29 Blood glucose was significantly enhanced in the
db/db mice compared to nondiabetic db/m mice (db/db:
20.84±1.6 mmol/l, db/m: 3.98±0.29 mmol/l, Po0.01,
n¼ 5). db/db mice at 4 months also revealed a significant
increase in serum CML and pentosidine compared to
nondiabetic db/m littermates (CML: db/m: 1.15±0.01,
db/db: 1.86±0.05* nmol/ml; pentosidine: db/m: 6.27±0.45,
db/db:12.68±0.06* pmol/ml; n¼ 3, *Po0.05 versus db/m).
There was a reduced staining for NRP1 in the glomeruli
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Figure 5 | Effect of neuropilin-1 on podocyte migration. Podocytes migration was analyzed in transwell system. (a) Downregulation of
NRP1 using siRNA technology reduced podocyte migration. Podocytes were transiently transfected with two different murine NRP1 siRNA
primer sets (Pr. 2 and Pr. 3) or a scramble primer as negative control (Neg. co). After transfection, podocytes were allowed to migrate for
24 h. The upper panel of the figure represents a Western blot demonstrating that Pr. 2 and Pr. 3, but not the scrambled primer (Neg. co),
reduced NRP1 protein expression. The lower panel shows the results from the migration assay performed after inhibition of NRP1
expression using siRNA. AGE-BSA suppressed and 10% FCS stimulated podocyte migration in the presence of the scrambled primer (Neg.
co). However, reduction of NRP1 expression by two different siRNA strongly suppressed podocyte migration even in the absence of
AGE-BSA. In these cells, AGE-BSA did not further reduce the migration ability suggesting that no other mechanism besides suppression of
NRP1 was operative (n¼ 5, *Po0.05 versus Co-BSA, **Po0.01 versus Co-BSA, #Po0.01 versus cells transfected with the scrambled control
primer (Neg. co). (b) Overexpression of NRP1 stimulates migration of podocytes. Transient transfection with the empty pcDNA3 vector
did not modulate the AGE-BSA-induced downregulation of NRP1 as shown in this Western blot. (c) Forced NRP1 overexpression is not
sensitive to AGE-BSA treatment and NRP1 protein levels remain high even in the presence of AGE-BSA. These Western blots represent three
different transfection experiments. (d) Migration assay. Transfection of podocytes with the empty pcDNA3 vector does not interfere with
either the AGE-BSA induced reduction or the stimulation of migration induced by 10% FCS. Pools 1 and 2 refer to two different batches of
podocytes being transfected with pcDNA3NRP1. Overexpression of NRP1 significantly stimulated migration of podocytes even in the
presence of AGE-BSA and also further increased migration compared with 10% FCS in two different culture batches of podocytes (n¼ 16,
*Po0.05 versus Co-BSA, **Po0.01 versus Co-BSA, #Po0.01 versus pcDNA3 of each condition).
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of the db/db mice compared to the db/m animals (Figure 8a
and d). To further test the localization of NRP1 expression,
kidney sections were double-stained with an antibody against
synaptopodin (Figure 8b and e). The double stainings
merged (Figure 8c and f) indicating almost an identical
expression pattern of NRP1 and synaptopodin. Real-time
PCR showed a significant downregulation of NRP1 and Sema
3F mRNA expressions, but not of NRP2 and Sema 3A, in
isolated glomeruli from the db/db mice compared with the
nondiabetic db/m littermates (Figure 9).
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Figure 6 | Apoptosis. (a,b) Immunohistological detection of caspase activity in podocytes using the cell permeable CaspACE-FITC-VAD-FMK
in sSitu marker. Podocytes were incubated with RPMI supplemented with 0.1% FCS, Co-BSA, or AGE-BSA for 24 h, followed by 30 min
exposure to FITC-labeled pan-caspase inhibitor. (a) Detection of caspase activity in podocytes transfected with a nonsilencing co-siRNA.
Nuclei were counterstained with DAPI. There are no detectable green apoptotic cells and AGE-BSA did not induce binding of the CaspACE-
FITC-VAD-FMK in situ marker. (b) Detection of caspase activity in podocytes transfected with NRP1 siRNA. In contrast to (a), suppression of
NRP1 expression by siRNA technology clearly increased the number of green, apoptotic cells. Original magnification  400. This experiment
was independently performed four times with similar results. (c) Analyses of podocyte transfection efficiency. Semiquantitative RT-PCRs
of mRNA expression of NRP1, NRP2, and GAPDH from podocytes transfected with either NRP1 siRNA or nonsilencing control siRNA
(co-siRNA) were performed in parallel to the immunohistological detection of caspase activity. NRP1 siRNA suppresses effectively and
specifically NRP1 mRNA but has no effect on NRP2 or GAPDH mRNA expressions and also reduced NRP1 protein expression (see Figure 5a).
M¼ size marker. (d) Apoptosis as measured by DNA-laddering. In podocytes transfected with co-siRNA or untransfected (data no shown)
AGE-BSA (5 mg/ml for 24 h) failed to degrade genomic DNA. In contrast, inhibition of NRP1 with siRNA induced DNA laddering even in the
absence of AGE-BSA. This experiment was independently performed three times with similar results. M¼ size marker.
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Expression of NRP1 and NRP2 is reduced in human kidney
biopsies from patients with diabetic nephropathy
To further confirm our findings for the human kidney, 15
biopsies of patients with diabetic nephropathy from the
European Renal cDNA Bank were investigated.30 All patients
had a serum creatinine 41.4 mg/dl and clinical details have
been previously reported.31 Normal renal biopsies from
living related donors (n¼ 8) served as control. Only
microdissected glomeruli were studied. The mRNA expres-
sion of NRP1 as well as NRP2 was significantly lower in
diabetic nephropathy compared with normal kidneys (NRP1:
normal controls: 0.0080±0.0067, diabetic nephropathy:
0.0035±0.0018 NRP1/18S rRNA expression, Po0.05;
NRP2: normal controls: 0.013±0.016, diabetic nephropathy:
0.0040±0.0036 NRP2/18S rRNA expression, Po0.05).
DISCUSSION
High concentrations of ambient glucose induced podocyte
hypertrophy and stress in vitro, suggesting that the podocyte
is a likely target of the diabetic milieu.32 We and others
reported an increased p27Kip1 expression predominantly in
podocytes, as the main immunolocalization was detected in
podocytes of diabetic rats as well as a high glucose medium
induced cell hypertrophy accompanied by the cell-cycle
inhibitor p27Kip1 upregulation in differentiated podocyte cell
lines.33 We recently described that AGE-BSA inhibited
proliferation by arresting podocytes in the G1-phase of the
cell cycle, a process that was mediated by p27Kip128. Although
transforming growth factor-b may play a role,34 the full effect
of AGEs on podocytes has not yet been clarified and the
genetic programs underlying phenotypic changes of podo-
cytes in response to AGEs have been incompletely studied.
Using differential display analysis, we identified NRP1 as
one of the genes downregulated by AGE-BSA. AGE-BSA
mediated suppression of NRP1 was specific for podocytes
and was not caused by unspecific toxic or apoptotic effects of
AGE-BSA.
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Figure 7 | Effect of VEGF and AGE-BSA on podocytes BrdU
incorporation as a measurement of proliferation. (a) BrdU
incorporation was performed using 5 103 cells/well in 96-well
plates. 1 ng/ml alone VEGF induced cells proliferation, but failed
to attenuate the AGE-BSA-mediated reduction in BrdU
incorporation. In comparison with AGE-BSA alone, addition of
VEGF to AGE-BSA further reduced proliferation (n¼ 36, *Po0.05
versus control, **Po0.01 versus Co-BSA, ***Po0.05 versus VEGF
plus Co-BSA, ****Po0.05 versus AGE-BSA). (b) Podocytes were
plated at a density 5 103 cells/well and were transfected with
NRP1 siRNA or control (co) siRNA for 24 h. Podocytes were then
incubated with 0.1% FCS (control), Co-BSA or AGE-BSA for 24 h
and BrdU incorporation was measured. NRP1 downregulation
significantly reduced proliferation in all three conditions. AGE-BSA
also significantly reduced BrdU incorporation compared to
Co-BSA-treated podocytes. n¼ 36, #Po0.05 versus co-siRNA of
the same treatment groups, *Po0.05 versus Co-BSA.
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Figure 8 | Immunohistological detection of NRP1 in kidney
glomeruli from diabetic db/db and nondiabetic db/m mice.
Diabetic (db/db) and nondiabetic (db/m) mice were perfused and
stained for NRP1 (a and d) or synaptopodin (b and e). db/db mice
revealed a decrease in NRP1 staining compared to db/m mice that
localized mainly to podocytes as shown in the merged images
(c and f). Original magnification  400.
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NRP1 expression was also suppressed in podocytes of the
diabetic db/db mice compared to nondiabetic db/m litter-
mates. Although we used double staining of podocytes with
the marker synaptopodin, we cannot totally rule out that
some mesangial cells also expressed NRP1 in db/db mice.
However, we believe that the majority of cells exhibiting
downregulation of NRP1 expression in db/db mice are
podocytes and AGE-BSA failed to suppress NRP1 in cultured
mouse mesangial cells. Real-time RT-PCR using RNA-
prepared isolated glomeruli suggested a decrease in NRP1
transcripts, but not of NRP2. As NRP2 is mainly expressed in
lymphatic vessels,35 one may argue a downregulation of
NRP2 is obscured by the presence on lymphatic vessels, but
we think that this possibility is not very likely because
isolated glomeruli were used for RNA preparation.
In addition, we clearly demonstrated that our findings
from cell culture and animal models appear to be true also
for the human kidney because patients with diabetic
nephropathy revealed significantly less mRNA expression of
NRP1 and NRP2 compared with normal kidneys. Certainly,
this initial study is limited and it remains to be tested
whether these findings are specific for diabetic nephropathy
or may also occur in other human glomerulopathies.
NRP1 is a type I cell surface coreceptor that plays
important roles in the development of the nervous system
and angiogenesis.36–38 Recently, NRP1 expression in the
kidney and particularly in podocytes has been reported.16–17
During neuronal development, NRP1-mediated signal trans-
duction requires the formation of a functional Sema 3A/
NRP1/Plexin A1 complex, which inhibits the axonal guiding
signal to the projecting neurons.24 In endothelial cells, NRP1
enhances the interaction between the heparin binding
VEGF164/165 with its VEGFR2 and modulates VEGF-depen-
dent angiogenesis.39,40 We found that AGE-BSA specifically
affect the expression of the NRP1 and NRP2 receptor
complexes and their ligands Sema 3A and Sema 3F.
Stimulated by recent studies by Gallichio et al.22 showing
that AGEs are capable of regulating tubulogenesis and
migration of kidney epithelial cells, as well as a potential
involvement of NRP1 in cell movement in other cell types, we
performed migration studies in podocytes treated with AGE-
BSA or Co-BSA. AGE-BSA inhibited the migration of
podocytes. We clearly showed through various approaches
that this effect was mediated by a downregulation of NRP1.
Our study using anti-NRP1 siRNA technology as well as
forced overexpression of NRP1 demonstrated that the
decrease in podocyte migration induced by AGE-BSA is not
an unspecific toxic effect, but depended on the suppression of
one gene, namely NRP1. We also addressed VEGF dependent
migration in podocytes. Under our experimental conditions
VEGF did only marginally, but not significantly, stimulated
migration. However, VEGF attenuated the AGE-BSA reduced
podocyte migration. We are convinced that the AGE-BSA-
induced downregulation of NRP1 leading to a decrease in
podocyte migration is detrimental for podocyte structure and
function, as the inability of podocytes to migrate leads to
‘nude’ areas of the glomerular basement membrane which
subsequently adheres to Bowman’s capsule initiating focal
glomerulosclerosis.11,41
In accordance with previous studies from our group,
AGE-BSA alone did not induce apoptosis of podocytes.28
However, total silencing of NRP1 with siRNA technology
readily induced apoptosis of podocytes as measured by two
different assays. This finding suggests that the AGE-BSA-
mediated downregulation of NRP1 by approximately 60% is
not sufficient to induce apoptosis. As a speculation, if
additional factors, induced by the diabetic environment, lead
to further NRP1 reduction, apoptosis may occur and
contribute to podocytes loss in diabetic nephropathy.
Guan et al.16 have recently also described the presence of
the semaphorin system in podocytes. Interestingly, they
found that podocytes exposed to recombinant exogenous
Sema 3A induced downregulation of podocin and decreased
its interaction with CD2-associated proteins and nephrin.42
Although it is difficult to compare endogenous to exogenous
concentrations of Sema 3A, a downregulation of Sema 3a by
AGE-BSA as found in our study can be seen as an ultimately
unsuccessful attempt to maintain the homeostasis of slit-
diaphragm proteins and to counteract apoptosis. On the
other hand, it has been found that the VEGF-A system is
necessary for upregulation of podocin and its interaction
with CD2AP.42 Moreover, VEGF-A is also required for
mesangial cell survival and differentiation.25,26 As NRP1
and NRP2 are coreceptors for VEGF, a downregulation of
NRP1 and NRP2 may attenuate VEGF signaling, particularly
in light of the fact that not all studies have found expression
of VEGFR1 and VEGFR2 receptors on podocytes. Indeed, a
recent study has shown that glycated albumin interferes with
VEGF signaling.43 We were able to confirm that VEGFR2 is
NRP1 NRP2 Sema 3A Sema 3F
m
R
N
A 
ex
pr
es
sio
n 
%
 o
f d
b/
m
  
0
20
40
60
80
100
120
140
160
180
*
db/db
db/m
**
Figure 9 | NRP1 mRNA expression is reduced in kidneys from
diabetic db/db mice. Total RNAs were prepared from isolated
glomeruli, and were reverse transcribed and subjected to real-
time PCR. mRNA expressions of NRP1, NRP2, Sema 3A, and Sema
3F were analyzed. mRNA expression is presented as a percent of
non¼diabetic db/m mice. Only NRP1 and Sema 3F, but not NRP2
and Sema 3A, mRNA expressions were reduced in glomeruli
harvested from db/db mice (n¼ 6 individual mice in each group,
*Po 0.05, **Po0.001 versus nondiabetic db/m mice).
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expressed in cultured podocytes but its expression is very
low compared to the NRP1 expression. We believe that
our data also demonstrate that proliferation and migration
of podocytes are complexly associated. VEGF plays a
role in podocytes survival but fails to attenuate the
AGE-BSA-induced reduction in proliferation, presumably
because AGE-BSA arrests the cells in the G1-phase via a
mechanism involving p27Kip1 induction that cannot be
overcome even in the presence of VEGF.28 Tapia et al.44
recently described that exogenous Sema 3A decreased
VEGFR2 receptor signaling and causes acute proteinuria that
was antagonized by administration of VEGF. These very
interesting findings indicate that a delicate balance of Sema
3A and VEGF is important for glomerular filtration barrier
homeostasis. We suggest that this balance can be also
disturbed by suppression of NRP1, and the complex
interactions among NRP1, Sema 3A, and VEGF certainly
require further studies.
In summary, our data show that AGE-BSA suppresses the
NRP1 and NRP2 receptor systems and that this leads to a
decrease in podocyte migration. These pathophysiological
changes may have profound implications for podocyte
pathology through various mechanisms in diabetic
nephropathy.
MATERIALS AND METHODS
Preparation of AGE-BSA
BSA (Fraction V, fatty acid-poor, endotoxin-free; Calbiochem, La
Jolla, CA, USA) was incubated under sterile conditions at 37 1C for
50 days in phosphate-buffered saline (PBS) with and without the
addition of glucose 90 mg/ml and filtrated (Millipore Labscale TFF
System, Billerica, MA, USA), extensively dialyzed against PBS,
glucose concentration measured (hexokinase method), and lyophi-
lized. Samples (2 mg/ml AGE-BSA) from different time points (5–50
days) were measured at an emission of 420 nm after excitation at
355 nm using a fluorescence reader FLUOstar OPTIMA (BMG
Labtech, Offenburg, Germany). CML was measured by an ELISA
(Roche Diagnostics, Mannheim, Germany) and pentosidine was
determined by HPLC as previously described.13,14
Cells and cell culture
Conditionally immortalized mouse podocytes were grown in RPMI
1640 medium with stable glutamine (PromoCell GmbH, Heidelberg,
Germany) supplemented with 10% heat-inactivated FCS in the
presence of recombinant mouse g-interferon (10 U/ml) for 3 weeks
at 33 1C and 5% CO2.
12,45 Removal of the g-interferon and
temperature switch to 37 1C induced podocyte differentiation.
Differentiated podocytes were tested positive for synaptopodin by
immunohistochemistry. These differentiated podocytes, named later
only podocytes, were used for our experiments. Mouse mesangial
cells18 and mouse epithelial tubular cells,19 were grown in Dulbecco’s
modified Eagle’s medium with stable glutamine containing 10%
heat-inactivated FCS. Mouse VEGF165 was ordered from Sigma
(Taufkirchen, Germany) and used in concentration 1 and 10 ng/ml.
Differential display
Mouse podocytes were incubated with AGE-BSA (5 mg/m) or the
same concentration Co-BSA for 24 h in the presence of 0.1% FCS.
Total RNA was isolated with the RNA easy kit (Qiagen, Hilden,
Germany) from both groups. Differential display PCR was
performed with RNAimage GenHunter (WAK-Chemie Medical,
Steinbach, Germany) and was theoretically capable of amplifying
gene sequences by 24 combinations of three 1-base anchored
oligo-dT primers (H-T11A, C, G) and eight random 13-mer primers
(AP1-8). Briefly, 0.2 mg DNA-free total RNA was reverse transcribed
by oligo-dT primer to produce the first-strand cDNA. One-tenth of
the first-strand reaction mixture was used as a template for PCR,
which was performed according to the following conditions: 94 1C
for 3 min; 40 cycles at 94 1C for 30 s, 40 1C for 2 min, and 72 1C for
1 min; and 72 1C for 5 min. a-[33P]dATP was incorporated into the
PCR products, which were displayed on a 6% denatured sequencing
gel and visualized by autoradiography. The candidate differentially
expressed fragments were cloned into the vector pCRII-TOPO
(Invitrogen, Karlsruhe, Germany) and sequenced. The sequences were
subjected to BLAST search for further analysis and identification.
Reverse-transcription and semiquantitative polymerase
chain reaction
Total RNA was isolated from 1 106 podocytes cultured for 24 h in
RPMI 1640 medium containing 0.1% heat inactivated FCS, or RPMI
1640 medium supplemented with 0.1% FCS plus Co-BSA (5 mg/ml)
or with 0.1% FCS plus AGE-BSA (5 mg/ml). cDNA was generated
from 1–2 mg total RNA using M-MLV Reverse Transcriptase kit
(Invitrogen). From the resulting cDNA 2 ml were subjected to PCR
amplification by the use of gene specific primers (Table 2). PCR
amplifications were performed as follows: 95 1C for 5 min, 95 1C for
45 s, annealing temperature as indicated in Table 2 for 45 s, 72 1C for
45 s, repeated 30–35 cycles, and a last elongation step at 72 1C for
5 min. The cDNA for mouse GAPDH was amplified as a control.
Table 2 | Sequence and annealing temperature of the primers
used for sem-quantitative and real-time PCR analyses of the
corresponding genes
Primer Sequence
Annealing
temperature
(1C)
NRP1 Fw 50-GAAGGCAACAACAACTATGA-30 58 1C
Rev 50-ATGCTCCCAGTGGCAGAATG-30
NRP2 Fw 50-AAGTGGGGGAAGGAGACTGT-30 58 1C
Rev 50-GTCCACCTCCCATCAGAGAA-30
Sema 3A Fw 50-GTTGTAGACCGGGTGGATGC-30 58 1C
Rev 50-TCGGAGCAGTGAGTCAGTGG-30
Sema 3B Fw 50-GAGGACTCTGCCGCTATCAC-30 56 1C
Rev 50-CTCCACACCCAACACCTTCT-30
Sema 3F Fw 50-AGGTGGATGCAGCTGATGG-30 60 1C
Rev 50-GGAATTGAAACCACGGCACT-30
Sema 3C Fw 50-GCAAAATGGCTGGCAAAGATCC-30 60 1C
Rev 50-CCCATGAAATCTATATACATTCC-30
PxA1-3 Fw 50-CCTCGAGAACAAGAACCACCCCAA-30
PxA1 Rev 50-CCCTTCACCGGCACCTCAGGTGCATT-30 58 1C
PxA2 Rev 50-AACACCTTCACTGGGATCTCTGGACTGTTC-30 60 1C
PxA3 Rev 50-CTTCACTGGGACCTGGGCGCTGCC-30 56 1C
PxB2 Fw 50-GATGGAGGACCAGACGAATGA-30 58 1C
Rev 50-CAGACCTGCGCAGCATTAGC-30
VEGFR2 Fw 50-GCTTTCGGTAGTGGGATGAA-30 58 1C
Rev 50-TTGGTGAGGATGACCGTGTA-30
GAPDH Fw 50-TGTCAGCAATGCATCCTGCA-30 60 1C
Rev 50 GATGTCATCATACTTGGCAGGTT-30
b-Actin Fw 50-GATGATGCAGATAATGTTTGAAAC-30 60 1C
Rev 50-GAGCAATGATCTTAATCTTCATTGTG-30
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Cloning of the mouse NRP1 gene
Murine NRP1 gene was amplified from cDNA synthesized from the
total RNA isolated from podocytes grown in normal growth
medium. The gene was amplified in two fragments using the
following primers: mNP1F/NRP1R and NRP1F/mNP1R from
Table 2. The amplified fragments were cloned into the PCRII-
TOPO vector and further cloned into pcDNA3. The NRP1 gene was
completely sequenced by automatic sequencing.
Real-time RT-PCR
Real-time PCR for mRNA determination was done in a final volume
of 20 ml containing 1 ml of cDNA, 0.5mM of each sense and antisense
primers, and 4 ml master mix of Lightcycler FastStart DNA
Master PLUS SYBR Green I kit from Roche Applied Science
(Mannheim, Germany). Real-time PCR reactions were performed
on a LightCycler instrument (Eppendorf AG, Hamburg, Germany)
according to the standard manufacturer protocols. The expression of
the gene of interest and GAPDH mRNA was analyzed with
monoplex analysis in which the target gene and the housekeeping
gene (GAPDH) were simultaneously determined in two different
reactions, both detected under the same dye (SYBR Green) in a
96-well plate. The measurements for the target gene and GAPDH
mRNAs were set up as subassays. The threshold cycle (CT)
represents the PCR cycle at which an increase of the reporter
fluorescence above the baseline is first detected. The relative
quantification analysis module is used to compare expression levels
of the target gene among differently treated samples. The expression
levels are calculated using the DDCT method.
46 A prerequisite to
yield valid relative expression values is that the efficiency is
comparable and close to 1 in the PCR systems of both the target
and the housekeeping gene. The expression levels R are calculated as
follow: R¼ 2DDCT (where R¼ 2 (DCT treatedDCT control)).
Downregulation of NRP1 with Mouse NRP1 siRNA
Podocytes were plated in six-well plates at density 2 105 to 3 105
cells/well in 1 ml RPMI medium, containing 8% FCS. The next day
the cells were transfected using HiPerfect transfection reagent
(Qiagen) with two different mouse NP1 siRNA primers
Mm_Nrp1_2 HP siRNA and Mm_Nrp1_3 HP siRNA and a control
primer (all from Qiagen) following the manufacturer instructions.
Concentrations of 10 nM (75 ng) and 20 nM (150 ng) from the
corresponding mouse NRP-1 siRNA primers, or the same
concentrations of the scramble primer, were used for transfection.
The cells were incubated with the transfection complexes under
normal growing conditions RPMI medium, 8% FCS. Twenty-four
hours after transfection the suppression of NRP-1 mRNA was
confirmed by RT–PCR using the Mm_Nrp1_1_SG QuantiTect
Primer Assay (Qiagen) and cells were then further subjected to
different assays and analysis as needed. All experiments were
performed in triplicates.
Western blot analysis
Podocytes were incubated as described, washed with PBS, and lysed
in buffer containing 50 mM Tris-HCL, pH 7.4; 100 mM NaCl; 2.5 mM
MgCl2; 1% Triton X-100, supplemented with 1 mM PMSF, 1 mM
Na3VO4, and cocktails of protease inhibitors (Boehringer,
Mannheim, Germany). SDS–polyacrylamide gel electrophoresis
and Western blotting were performed as described elsewhere.35 To
assess the protein expression of NRP-1 and NRP-1 the membrane
was further incubated for an additional 1 h with polyclonal
antibodies against mouse NRP-1 as well as NRP-2 (Abcam,
Cambridge, UK) in dilution 1:500 in 5% BSA-TBST, washed several
times with TBST, and incubated for 1 h with a horseradish
peroxidase conjugated goat anti-rabbit secondary antibody
(1:5000; KPL, Gaithersburg, MD, USA). The vinculin monoclonal
antibody was from Sigma. After intensive washing the proteins were
visualized with ECL detection reagent (Roth, Karlsruhe, Germany).
Cell migration assay
Podocytes were adjusted to a concentration of 0.5 106 to 1 106
cells/ml in serum-free medium and subjected to a transwell migration
assay using a Boyden chamber. Cell suspension (300ml) was plated on
8mm membrane pore size cell inserts (Nunc, Langenselbold, Germany)
in the upper chamber. 500ml of the medium containing the reagent
that needed to be tested was added to the lower chamber and the cells
were incubated for 24 h. All treatments were performed in triplicate.
After the incubation time, the inserts were placed in new wells
containing 200ml of the prewarmed accutase (Innovative Cell
Technologies, San Diego, CA, USA) and incubated for 30 min at
37 1C to remove the cells from the lower side of the insert by gently
shaking the insert back and forth several times during the incubation.
The total cell number for each separate well was counted in a Coulter
counter.
LDH release assay
Potential cytotoxicity induced by Co-BSA or AGE-BSA treatment
was evaluated by the quantification of the lactate dehydrogenase
release from damaged cells using the lactate dehydrogenase
cytotoxicity assay kit (BioVision Research Products, Mountain
View, CA, USA).
Proliferation assay
BrdU incorporation (Roche Diagnostics) was used as a parameter
for DNA synthesis. Podocytes were grown in a 96-microtiter plate
with 5000 cells/well. After that media was supplemented with
Co-BSA or AGE-BSA (5 mg/ml), or VEGF165 (1 or 10 ng/ml) and
incubated for another 24 h. BrdU labeling reagent was added for 4 h.
Fixation of cells, and detection of BrdU was performed according to
the manufacturer’s protocol. Each measurement was performed with
n¼ 12 per treatment group. The tests were independently repeated
three times.
Analysis of apoptosis
Podocytes were plated in chambers slides and were transfected with
20 nmol of each NRP1 siRNA, or nonsilencing control siRNA or
were left untransfected. Transfection mixtures were exchanged with
RPMI medium containing 0.1% FCS, Co-BSA, or AGE-BSA and the
cells were incubated for 24 h. CaspACE-FITC-VAD-FMK in situ
marker (Promega, Madison, WI, USA), a cell permeable fluorescent
analogue of the pan caspase inhibitor Z-VAD-FMK (carbobenzoxy-
valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone) was added at
a final concentration 5 mM for 30 min at 37 1C The cells were washed
twice with PBS, fixed with 10% formalin in PBS buffer for 30 min at
room temperature. Slides were washed three 3 times with PBS,
mounting medium and cover slips were added, and the cells were
analyzed under a fluorescence microscope Axioplan (Zeiss, Ger-
many). In addition, apoptosis was also assessed by DNA laddering.
Podocytes were plated at density 4 105 cells/well into six-well
plates and incubated as appropriate. Cells were washed once with
PBS and genomic DNA was isolated using DNAeasy Tissue kit
(Qiagen) according to the manufacturer’s instructions. Finally, the
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genomic DNA was eluted with 100ml buffer. After that the quality of
the purified genomic DNA was analyzed on 0.8% agarose gel.
Animal experiments
Animal experiments were approved by the local Animal Care
Committee of the University of Jena and done in accordance with
the German Animal Protection Law. Male db/db (B6.Cg-mþ /þ
Leprdb/J; Jackson Laboratory, Bar Harbor, ME, USA) mice at 4
months and their age-matched nondiabetic db/m littermates were
used. Kidneys were perfusion fixed before harvesting. In addition,
kidneys were also harvested without perfusion and glomeruli were
isolated by differential sieving techniques as described.18
Immunocytology and immunohistochemistry
For cultured podocytes, cells were grown on glass cover slips at a
density of 4 105 and were incubated with Co-BSA or AGE-BSA for
an additional 24 h. Cells were fixed with 4% paraformaldehyde, and
synaptopodin was detected with a rabbit antibody (Sigma) and
indirect immunocytochemistry. Immunohistochemistry was per-
formed as described elsewhere in detail.47 The primary NRP1 rabbit
antibody (Calbiochem) or synaptopodin (polyclonal goat, NE-14;
Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies were
used in dilution 1:250 and incubated overnight at 4 1C, and the
secondary antibody rabbit anti-goat-FITC conjugated (Delta
Biolabs, Gilroy, CA, USA) or donkey anti-rabbit-Cy3 conjugated
(Jackson ImmunoResearch Lab, West Grove, PA, USA), were used in
dilution 1:1000 for 3 h. Negative controls were performed using
nonimmune sera from the appropriate species to replace the
primary antibody. Cells or the kidney sections were washed several
times with PBS and embedded in Kaiser’s gelatin. For a double
staining on kidney slides first the sections were incubated with the
primary NRP1 antibody, then with the secondary antibody, followed
with new blocking and staining with anti-synaptopodin antibody.
Immunohistochemistry was performed on five different animals
from each group.
Human kidney biopsies
Human kidney biopsies were obtained from patients after informed
consent and with approval of local ethic committees as part of the
European Renal cDNA Bank. Material was submerged in an RNAse
inhibitor (RNAlater; Ambion, Austin, TX, USA) and microdissected
under standardized conditions at the core facility as previously
described.30 Pretransplant biopsies from 8 living donors served as
controls. A total of 15 biopsies from patients with diabetic
nephropathy were studied. The clinical details of these patients
have been previously described.31 NRP1 and NRP2 expression was
studied in microdissected glomeruli at the core facility by
established methods as previously described in detail.30 Predeve-
loped TaqMan reagents were used for human NRP1, NRP2, and 18S
rRNA on a 7500 Fast Real-Time PCR System (all Applied Biosystems,
Darmstadt, Germany). The mRNA expression was analyzed by
standard curve quantification. Normalization was performed for the
expression of the 18S rRNA housekeeping gene.30,31
Statistical analysis
All data are reported as means±standard deviation (s.d.). Statistical
analysis was performed using the statistical package SPSS for
Windows version 11.0 (SPSS Inc., Chicago, IL, USA). Results were
analyzed with the Kruskal–Wallis test followed by Mann–Whitney
U-test. Differences were considered significant when Po0.05.
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